Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla

Lupin signs distribution agreements in key EU territories for orphan drug NaMusclaAEnables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic disorders in three key territoriesZug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMusclaA (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMusculaA for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain EU territories. NaMusculaA is the first and only licensed product for this indication.NDM disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMusclaA reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional and clinical outcomes1. NaMusclaA, which has been designated orphan drug status, received EU marketing authorization in December 2018.Under the agreements announced today, Exeltis Healthcare S.L will commercialize NaMusclaA in Spain and Portugal, Cresco Pharma B.V will commercialize NaMusclaA in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMuscula A in Germany and UK and will launch the product in Austria and France later this year.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »